You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Tritum AMS Analysis of Cancer Biomarkers

    SBC: NEWTON SCIENTIFIC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase II STTR program is to develop a high-throughput, ultra-sensitive accelerator mass spectrometer for the detection and quantification of tritium in labeled biological molecules. Accelerator mass spectrometry (AMS) is a highly selective means for detecting tritium that can achieve a measurement sensitivity over 1000 times greater than decay ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  2. New Rapid Diagnostic Tests for Amebiasis

    SBC: TECHLAB, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Our goal is to produce point-of-care diagnostic tests for amebiasis. Entamoeba histolytica is a protozoan parasite and the causative agent of amebiasis in humans. Intestinal amebiasis causes debilitating diarrhea and dysentery, while extraintestinal amebiasis occurs when the parasite migrates from the intestinal tract to organs throughout the body, most commonl ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy

    SBC: TheraNano LLC            Topic: 102

    Theranano LLC in collaboration with internationally renowned prostate brachytherapy clinicians at Brigham and Womens Hospital and Dana Farber Cancer Institute and biomaterials experts at Northeastern University have developed an innovative combinatorial treatment strategy of Local ChemoRadiation Therapy (LCRT) using a modified brachytherapy spacer platform in the form of a INCeRT (ImplaNts for Che ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma

    SBC: Cyteir Therapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Herpes Simplex Immunotherapeutic Vaccine

    SBC: VICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Herpes simplex viruses infect humans worldwide. In the US, herpes simplex virus type 2 (HSV-2) infects about 17% of adults. Rates are far higher in the developing world, especially in populations with high HIV-1 prev alence. HSV-2 infections are permanent and the virus establishes latency in dorsal root ganglia neurons after infection. Periodic reactivatio ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Human monoclonal antibodies for prevention of S. aureus infections

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Using mouse monoclonal antibodies mAbs raised against the mediators of quorum sensing QS the Auto Inducing Peptides AIPs researchers at The Scripps Research Institute TSRI have demonstrated that S aureus infections can be prevented in animal challenge models This approach known as quorum quenching QQ is unique in at least two significant ways fi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: NCI

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A user-friendly scalable microfluidic platform for enhanced neuron-cell culture

    SBC: Xona Microfluidics, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantNeuron cell culture is widely used for studies in basic researchdrug discoveryand toxicity testingTraditional neuron cell culture approaches result in random growth of processes which prevent the study of their unique polarized morphologyOur goal is to provide robustuser friendlyand cost effective culture platforms to manipulate and access neurons and their subcellu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida species are opportunistic fungal pathogens that have become among the most common causes of nosocomial infections in the United States and worldwide. Disseminated infections caused by Candida spp. have increased 15-fold in incidence in the last 15 years, and Candida is now the third most common cause of bloodstream infections. Even with modern antifunga ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections

    SBC: EXBAQ LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Two million Healthcare Associated Infections (HAIs) occur per year in the US, killing rt90,000 patients and costing ~$50-100 billion (adjusted by CPI to 2020 dollars). HAIs are the 6th leading cause of death in the US, ahead of diabetes and kidney disease. Reducing HAIs is a top priority of the US Department of Health and Human Services1 and experts have called for novel s ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government